Matteo Molica

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2017-2023
Publications (10 Years): 15

Top Topics

Body Mass Index

Allogeneic Hematopoietic Stem Cell Transplantation

Tyrosine Kinase

Chronic Myeloid Leukemia

Top Venues

Annals of hematology

American journal of hematology

British journal of haematology

This page only lists publications with an associated author ORCID identifier.

Publications

Matteo Molica, Salvatore Perrone, Marco Rossi
Gilteritinib: The Story of a Proceeding Success into Hard-to-Treat FLT3 -Mutated AML Patients. Journal of clinical medicine 12 (11) (2023)
Matteo Molica, Salvatore Perrone, Vincenzo Federico, Caterina Alati, Stefano Molica, Marco Rossi
Venetoclax: A Game Changer in the Treatment of Younger AML Patients? Cancers 16 (1) (2023)
Matteo Molica, Salvatore Perrone, Vincenzo Federico, Caterina Alati, Stefano Molica, Marco Rossi
Venetoclax: A Game Changer in the Treatment of Younger AML Patients? Cancers 16 (1) (2023)
Matteo Molica, Salvatore Perrone, Costanza Andriola, Marco Rossi
Immunotherapy with Monoclonal Antibodies for Acute Myeloid Leukemia: A Work in Progress. Cancers 15 (20) (2023)
Martina Canichella, Matteo Molica, Carla Mazzone, Paolo de Fabritiis
Chimeric Antigen Receptor T-Cell Therapy in Acute Myeloid Leukemia: State of the Art and Recent Advances. Cancers 16 (1) (2023)
Martina Canichella, Matteo Molica, Carla Mazzone, Paolo de Fabritiis
Chimeric Antigen Receptor T-Cell Therapy in Acute Myeloid Leukemia: State of the Art and Recent Advances. Cancers 16 (1) (2023)
Matteo Molica, Salvatore Perrone, Carla Mazzone, Laura Cesini, Martina Canichella, Paolo de Fabritiis
CPX-351: An Old Scheme with a New Formulation in the Treatment of High-Risk AML. Cancers 14 (12) (2022)
Matteo Molica, Carla Mazzone, Pasquale Niscola, Ida Carmosino, Ambra Di Veroli, Cinzia De Gregoris, Fabrizio Bonanni, Salvatore Perrone, Natalia Cenfra, Luana Fianchi, Anna Lina Piccioni, Antonio Spadea, Giovanni Luzi, Andrea Mengarelli, Laura Cudillo, Luca Maurillo, Livio Pagano, Massimo Breccia, Luigi Rigacci, Paolo De Fabritiis
Identification of Predictive Factors for Overall Survival and Response during Hypomethylating Treatment in Very Elderly (≥75 Years) Acute Myeloid Leukemia Patients: A Multicenter Real-Life Experience. Cancers 14 (19) (2022)
Matteo Molica, Salvatore Perrone
Molecular targets for the treatment of AML in the forthcoming 5th World Health Organization Classification of Haematolymphoid Tumours. Expert review of hematology 15 (11) (2022)
Matteo Molica, Carla Mazzone, Iole Cordone, Alessia Pasquale, Pasquale Niscola, Paolo De Fabritiis
SARS-CoV-2 infection anxieties and general population restrictions delay diagnosis and treatment of acute haematological malignancies. British journal of haematology 190 (1) (2020)
Matteo Molica, Gioia Colafigli, Emilia Scalzulli, Danilo Alunni Fegatelli, Sofia Chiatamone Ranieri, Lorenzo Rizzo, Daniela Diverio, Fabio Efficace, Roberto Latagliata, Robin Foà, Massimo Breccia
Ten-year outcome of chronic-phase chronic myeloid leukemia patients treated with imatinib in real life. Annals of hematology 98 (8) (2019)
Giovanni Caocci, Olga Mulas, Mario Annunziata, Luigiana Luciano, Massimiliano Bonifacio, Ester Maria Orlandi, Patrizia Pregno, Sara Galimberti, Antonella Russo Rossi, Elisabetta Abruzzese, Alessandra Iurlo, Bruno Martino, Nicola Sgherza, Gianni Binotto, Fausto Castagnetti, Antonella Gozzini, Claudio Fozza, Monica Bocchia, Anna Sicuranza, Fabio Stagno, Fabio Efficace, Emilio Usala, Fiorenza De Gregorio, Luigi Scaffidi, Chiara Elena, Francesca Pirillo, Claudia Baratè, Malgorzata Monika Trawinska, Daniele Cattaneo, Claudia Labate, Gabriele Gugliotta, Matteo Molica, Giorgina Specchia, Giorgio La Nasa, Robin Foà, Massimo Breccia
Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis. American journal of hematology 93 (7) (2018)
Matteo Molica, Emilia Scalzulli, Gioia Colafigli, Danilo Alunni Fegatelli, Fulvio Massaro, Roberto Latagliata, Robin Foà, Massimo Breccia
Changes in estimated glomerular filtration rate in chronic myeloid leukemia patients treated front line with available TKIs and correlation with cardiovascular events. Annals of hematology 97 (10) (2018)
Matteo Molica, Martina Canichella, Gioia Colafigli, Roberto Latagliata, Daniela Diverio, Giuliana Alimena, Robin Foà, Massimo Breccia
Body mass index does not impact on molecular response rate of chronic myeloid leukaemia patients treated frontline with second generation tyrosine kinase inhibitors. British journal of haematology 182 (3) (2017)
Matteo Molica, Martina Canichella, Danilo Alunni Fegatelli, Gioia Colafigli, Fulvio Massaro, Roberto Latagliata, Robin Foà, Massimo Breccia
The Eutos long-term survival score accurately predicts the risk of death in chronic myeloid leukaemia patients treated outside of clinical trials. American journal of hematology 92 (12) (2017)